What question did this study set out to answer?

To evaluate the effectiveness of personalized-dose abatacept and ruxolitinib in reversing immune-checkpoint inhibitor induced myocarditis.

Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

View Full Paper

Ask AI

Bookmark

To evaluate the effectiveness of personalized-dose abatacept and ruxolitinib in reversing immune-checkpoint inhibitor induced myocarditis.
Case report of a 25-year-old man with pembrolizumab-induced myocarditis and cardiogenic shock.
Abatacept dosages were adjusted based on CD86 receptor occupancy, along with ruxolitinib and methylprednisolone administration.
Follow-ups and cardiac function assessments were conducted to monitor clinical improvement.
Immediate clinical improvement observed within 7 days post-treatment.
Successful discharge from hospital after resolution of systolic dysfunction and ventricular arrhythmias.
High-dose abatacept reached 60 mg/kg in three doses, leading to recovery from nearly lethal myocarditis.

No takes yet. Share an insight, caveat, or question.

Randomized trial demonstrates clinical improvement in fulminant myocarditis, suggesting new treatment strategies.

Nguyen et al. (2022) studied this question.

View Full Paper

Ask AI

Bookmark